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Abstract—Rheumatic fever (RF) is an autoimmune disease triggered by Streptococcus pyogenes
infection frequently observed in infants from developing countries. Rheumatic heart disease (RHD),
the major sequel of RF, leads to chronic inﬂammation of the myocardium and valvular tissue. T cells
are the main population inﬁltrating cardiac lesions; however, the chemokines that orchestrate their
recruitment are not clearly deﬁned. Here, we investigated the expression of chemokines and che-
mokine receptors in cardiac tissue biopsies obtained from chronic RHD patients. Our results showed
that CCL3/MIP1α gene expression was upregulated in myocardium while CCL1/I-309 and CXCL9/
Mig were highly expressed in valvular tissue. Auto-reactive T cells that inﬁltrate valvular lesions
presented a memory phenotype (CD4+CD45RO+) and migrate mainly toward CXCL9/Mig gradient.
Collectively, our results show that a diverse milieu of chemokines is expressed in myocardium and
valvular tissue lesions and emphasize the role of CXCL9/Mig in mediating T cell recruitment to the
site of inﬂammation in the heart.
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INTRODUCTION
Rheumatic fever (RF) is a post-infectious autoim-
mune disease triggered by the Gram-positive bacteria
Streptococcus pyogenes. The disease manifests initially as
polyarthritis, carditis/valvulitis, chorea, erythema margin-
atum, and/or subcutaneous nodules [1]. Arthritis, the
earliest feature of the disease, is present in 60–80 % of
patients [2]. Rheumatic carditis occurs a few weeks after
the streptococcal pharyngeal infection in 30 to 45 % of RF
patients and can lead to permanent disability. Recurrent
acute cardiac lesions frequently evolve into chronic
rheumatic heart disease (RHD), of which valvular defor-
mities are the most important chronic sequel, and lead to
mitral and aortic regurgitation and/or stenosis. Valve
replacement surgery is usually the only treatment remain-
ing for chronic RHD patients.
Previous reports have described rheumatic valvuli-
tis as a mononuclear cellular inﬁltrate made up mainly of
CD4+ and CD8+ T cells [3–6]. The expression of major
histocompatibility complex class II molecules has been
observed on vessel endothelium, valvular ﬁbroblasts,
and macrophage-like cells within the rheumatic lesions
[5–7]. Aschoff nodules/bodies, observed in the cardiac
tissue of some RF patients, are considered hallmarks of
active rheumatic carditis [8]. Aschoff bodies are granu-
lomatous structures consisting of ﬁbrinoid changes,
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lymphocytic inﬁltrate, occasional plasma cells, and
macrophages surrounding necrotic centers. Aschoff
body development is composed of three distinct phases.
The earliest phase is represented by degenerate and
ﬁbrinoid changes in the cardiac collagenous tissue. In
the intermediate proliferative or granulomatous phase,
the main histological features are inﬂammatory cell
proliferation and the presence of large macrophages
termed Anitschkow or caterpillar cells. The late or
cicatricial phase is represented by ﬁbrosis or healing of
the lesions [9].
Although substantial progress has been made in the
understanding of RF as an autoimmune disease, the
precise pathogenic mechanisms of RF have not been
completely deﬁned. Nevertheless, the current knowledge
in the ﬁeld emphasizes T and B cell activation by
streptococcal antigens as the main event triggered by the
infection.
Lymphocytic inﬁltration through the valve surface
endothelium appears to be the initiating step for tissue
damage and disease pathogenesis. A number of evidences
show that B cells, through the production of antibodies that
cross-recognize streptococcal antigens and cardiac tissue
proteins, such as laminin, vimentin, and myosin [10, 11],
are responsible for the valvular endothelium upregulation of
the adhesion molecule vascular cell adhesion molecule-1.
The binding of this molecule to very late antigen-4 on
activated T cells is apparently crucial for the extravasation
of CD4+ and CD8+ T cells through the valve-activated
endothelium [12].
The perpetuation of valvular injury however is
carried out by T cells that simultaneously recognize
streptococcal antigens and valvular tissue proteins
through molecular mimicry [6, 13]. Heart-inﬁltrating T
cells that contribute to the tissue inﬂammation mainly
secrete inﬂammatory cytokines such as IFN gamma and
TNF alpha [14].
T lymphocytes seem to be the main players in the
maintenance and perpetuation of valve damage; howev-
er, the molecules that orchestrate the recruitment of
inﬂammatory mononuclear cells and speciﬁc T cell
subsets to the myocardium and subsequently to the
valve lesion are not clearly deﬁned.
Chemokines are a group of small (8–14 kDa),
structurally related molecules that regulate cell trafﬁck-
ing through interactions with a subset of seven-trans-
membrane G protein-coupled receptors. They are
important mediators of cellular migration, contributing
not only to homeostatic migration but also to cellular
entry into sites of acute and chronic inﬂammation. The
milieu of chemokines and chemokine receptors
expressed by endothelial cells and leukocyte subsets
determines leukocyte recruitment for participation in
speciﬁc inﬂammatory pathologies.
In the present study, we investigated the expression
of chemokines and their respective receptors in myocar-
dium and valvular tissue from chronic RHD patients and




Severe chronic RHD patients who underwent
cardiac surgery for valve replacement were included in
the study (n023). Patients were followed at the Heart
Institute, University of São Paulo (SP) and at the Márcio
Cunha Hospital, Ipatinga (MG), Brazil. This study was
approved by both the Heart Institute Ethics Committee
(CAPPesq) from Clinical Hospital, School of Medicine,
University of São Paulo and Márcio Cunha Hospital
Ethics Committee. Informed consent was assigned from
all patients participating in the study or from the parents
or legal responsible of the patients under 18 years old.
The studied cohort was composed of 10 males and
13 females with a mean age of 24.31±16.06 years. All
patients had morphologic cardiac valve lesions (Table 1)
and most of them presented severe mitral and/or aortic
valve regurgitation (56.5 %: patients 1 to 13) and severe
mitral and aortic valve regurgitation and stenosis
(26.1 %; patients 14 to 19). Isolated valve stenosis was
found in 17.4 % of the patients (patients 20 to 23). Only
few patients were operated during acute RF episode
(patients 2, 4, 6, and 22) (Table 1). None of the patients
present medical history of other autoimmune disease and
were also not under any immunosuppressive drug
treatment.
Heart Tissue Samples
Heart tissue samples were collected during cardiac
surgery procedures for valve corrections in accordance
with the Hospital Ethics Committee.
Histopathology
Histological sections from cardiac tissue samples
were stained with hematoxylin–eosin and were reviewed
by two independent pathologists to evaluate histological
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features of acute and chronic RHD, such as inﬂamma-
tory inﬁltrates, rheumatic activity, neovascularization,
ﬁbrosis, and calciﬁcation.
Real-time qPCR
Total RNAwas extracted from heart tissue fragments
using Trizol® (Gibco, Life Technologies, Invitrogen
Corporation, Carlsbad, CA) according to the manufac-
turer’s protocol. Tissue disruption and homogenization
was performed using a rotor-stator homogenizer device
(Power Gen1000, Fischer Scientiﬁc, Hampton, NH). After
determining the optical density at 260 nm, RNA was
treated with DNase I (Invitrogen, Carlsbad, CA). Five
micrograms of RNA was reverse-transcribed into cDNA
using Superscript™ II Reverse Transcriptase (Invitrogen
Corporation, Carlsbad, CA). Gene expression levels of
chemokines and chemokine receptors were determined by
real-time qPCR using the ABI 7500 Sequence Detection
System (Applied Biosystems, Foster City, CA). Ampliﬁ-
cation was carried out for 40 cycles of 15 s at 95 °C and
1 min at 60 °C, and the product was detected using SYBR
Green dye (Molecular Probes Inc., Eugene, OR). Glycer-
aldehyde-3-phosphate dehydrogenase was used as an
endogenous control gene. Gene expression levels of heart
tissue fragments from patients who underwent cardiac
surgery due to non-inﬂammatory cardiac diseases were
used as reference controls. A list of the genes studied and
the primer sequences used is presented in Table 2. Samples
were run in triplicate and a dissociation curve analysis was
performed in each run to ensure speciﬁcity of the primers.
The relative gene quantiﬁcation of each gene was
calculated using the 2−ΔΔCt method [15].
Immunoﬂuorescence
Frozen heart tissue sections of 5 μm were ﬁxed with
acetone and rinsed with PBS containing 0.1 % Triton X-
100. Subsequently, the sections were incubated with PBS
containing 2 % BSA followed by an overnight incubation
at 4 °C with the primary antibodies. The following primary
antibodies were used: CCL1 (clone 35305), CCL3 (clone
93321), CXCL9 (clone 49106), CCR5 (clone 45523),
CXCR3 (clone 49801), FITC-conjugated CD14 (clone
TuK4), Alexa Fluor 488-conjugated CD4 (clone S3.5), and
Alexa Fluor 488-conjugated CD8 (clone 3B5; all uncon-
Table 2. List of Genes Studied and Primers Sequences Used for Real-Time PCR Ampliﬁcation
Genes Accession number Sequence Amplicon (bp) Concentration (nM)
CCL1 M57502 (F): GCTCCAATGAGGGCTTAATATTCA 91 200
(R): ATTTTTCTGTGCCTCTGAACCCAT
CCL3 AF043339 (F): ACCAGTTCTCTGCATCACTTGCT 110 200
(R): GCTGCTCGTCTCAAAGTAGTCAGC
CCL4 J04130 (F): GCTTCCTCGCAACTTTGTGGT 110 300
(R): CACTGGGATCAGCACAGACTTG
CCL5 M21121 (F): CGTGCCCACATCAAGGAGTATT 91 400
(R): CACACACTTGGCGGTTCTTTC
CXCL9 X72755 (F): TCTGATTGGAGTGCAAGGAACC 98 100
(R): GGTCTTTCAAGGATTGTAGGTGGA
CXCL10 X02530 (F): TCCACGTGTTGAGATCATTGCTA 93 300
(R): GCTTTCAGTAAATTCTTGATGGCC
CCL17 D43767 (F): CACATCCACGCAGCTCGA 98 200
(R): TGGTACCACGTCTTCAGCTTTCTA
CCL22 U83171 (F): CTGCGCGTGGTGAAACACTT 91 200
(R): CACAGATCTCCTTATCCCTGAAGGT
CCR4 X85740 (F): CCCTTCCTGGCTTTCTGTTCA 91 200
(R): TTCCACGTCGTGGAGTTGAGA
CCR5 U57840 (F): TCCGCTCTACTCACTGGTGTTCA 91 100
(R): CATGCTCTTCAGCCTTTTGCAG
CCR8 NM_005201 (F): ATGCCCTAAAGGTGAGGACGAT 91 200
(R): ACTAGCAATGGGATGGTAGCCA
CXCR3 NM_001504 (F): GTCCTTGAGGTGAGTGACCACC 106 200
(R): ACGAGTCACTCTCGTTTTCTCCA
GAPDH NM_002046 (R): TGGTCTCCTCTGACTTCA 117 200
(F): AGCCAAATTCGTTGTCAT
(F) forward sequence, (R) reverse sequence, bp base pair, GAPDH glyceraldehyde-3-phosphate dehydrogenase
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Table 3. Histopathological Data of Cardiac Tissue Fragments from RHD Patients
Patients (#) Tissue Inflammation ARF Activity Neovascularization Fibrosis Calcification
1 Ao.v. a + A + ++ A




















5 L.A. a A A NA NA NA












9 Ao.v. a A A + +++ A
10 L.A. a A A NA NA NA














13 Ao.v. a + A ++ ++ A
14 Mi.v. b +++ A +++ +++ ++
15 Mi.v. b + A A + A
16 Mi.v. b A A A ++ A
17 P.M. a + A NA NA NA
18 Ao.v. a + A ++ +++ +++
19 Ao.v. a b + A + +++ +
20 Mi.v. b + A + ++ A














23 Mi.v. a,b A A A ++ A
Mi.v. mitral valve, Ao.v. aortic valve, R.A. right atrium, L.A. left atrium, P.M papillary muscle, Peric. Pericardium, A absent, NA not analyzed, “+”
mild, “++” moderate, “+++” severe, ARF acute rheumatic fever
aChemokines and chemokine receptors gene expression determinates by real-time qPCR
bChemokines and chemokine receptors expression determinates by confocal microscopy
cAschoff bodies in proliferative phase
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jugated primary antibodies were purchased from R&D
Systems Inc., Minneapolis, MN, and all conjugated
primary antibodies were purchased from Invitrogen Cor-
poration Carlsbad, CA). After washing, the slides were
incubated with Alexa Fluor 633-conjugated anti-mouse or
Alexa Fluor 633-conjugated anti-rat secondary antibodies
(both from Invitrogen) and DAPI (4′,6-diamidino-2-phe-
nylindole, dihydrochloride, Sigma-Aldrich Corp., St.
Louis, MO) was used for nuclear staining. Fluorescent
images were acquired using UV/Laser excitation on an
LSM/Meta 510 Zeiss microscope and analysis was
performed using LSM Image Examiner software (Carl
Zeiss, Standort Göttingen, Germany). Unspeciﬁc staining
was excluded using sections stained only with primary
antibody as well as sections only with secondary antibody.
Chemotaxis Assays
Chemotaxis assays were performed using intrale-
sional T cell lines established from mitral or aortic valve
surgical fragments as previously described [6]; 2×106 T
cells were plated in a 5-μm transwell collagen-coated
device (Corning Costar Corp., Acton, MA). The migration
capabilities of T cells were evaluated in the presence of
CCL1/I-309, CCL3/MIP1α CCL17/TARC, and CXCL9/
Mig (all recombinant proteins were purchased from R&D),
which were added to the lower chamber diluted in DMEM
(Invitrogen, Life Technologies) at 50, 100, and 250 nM.
After 3 h incubation, the absolute number of cells that
transmigrated to the lower chamber was counted using a
Neubauer chamber. To determine which subsets of cells
transmigrated, a fraction of the cells that transmigrated to
the lower chamber was stained and analyzed by ﬂow
cytometry using a FACS Calibur cytometer for acquisition
and Cell Quest software for analysis (Becton &
Dickinson). The cells were stained with antibodies
against CD3, CD4, CD8, and CD45RO (all purchased
from Becton & Dickinson).
Statistics
Nonparametric tests speciﬁed in the ﬁgures legends
were used for comparisons of the gene expression of
chemokines and their receptors in myocardial and valvular
tissue as well as for migration assay using T cell lines. P
values of <0.05 were considered statistically signiﬁcant.
RESULTS
Fibrosis, Inﬂammation, and Neovascularization
are the Main Features of Rheumatic Heart Lesions
Cardiac tissue sections from 23 RHD patients who
underwent valve replacement surgery were analyzed for
Fig. 1. Chemokines and receptors gene expression at different sites of rheumatic heart disease lesions. Chemokine and chemokine receptor gene
expression was analyzed by real-time qPCR. Myo myocardium biopsies, Valve mitral and/or aortic valve biopsies. Statistical analysis was performed
using nonparametric Mann–Whitney U test, and P values of <0.05 were considered signiﬁcant and are depicted in the ﬁgure.
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the presence of rheumatic activity, inﬂammation, neo-
vascularization, ﬁbrosis, and calciﬁcation. Histological
analysis showed the presence of inﬂammation in 18 out
of 26 fragments analyzed. Fibrosis was observed in 16
out of 26 fragments and neovascularization was also
frequently observed (12 out of 26 fragments). Addition-
ally, Aschoff bodies, the hallmarks of rheumatic activity,
were observed in ﬁve tissue fragments of patients 2, 4, 6,
7, and 8 with acute RF episodes (Table 3).
CCL3/MIP1α, CCL1/I-309, and CXCL9/Mig
are Differentially Expressed in Myocardium
and Valvular Tissue Lesions
In order to identify whether distinct chemokines
and their respective receptors are involved in cell
recruitment to different sites of rheumatic lesions, we
compare gene expression of samples obtained from
myocardium and valvular tissue lesions from RHD
patients. Samples obtained from patients who underwent
cardiac surgery due to non-inﬂammatory disorders were
used as reference controls. The list of chemokines and
receptors analyzed is presented in Table 2.
Gene expression analysis showed that CCL1/I-309
and CXCL9/Mig were up-regulated in valvular tissue
compared with myocardium (P00.034 and 0.005, respec-
tively) (Fig. 1). In contrast, CCL3/MIP1α gene expression
was highly upregulated in myocardium samples when
compared with valvular tissue (P00.001) (Fig. 1). Of the
chemokine receptors examined, CCR5 and CCR8 gene
expression was upregulated in valvular tissue when
compared with myocardium (P00.021 and 0.013, respec-
tively) (Fig. 1). Although the CXCR3 receptor gene
expression did not reach a statistical signiﬁcance we
observed that 75 % (9 out of 12) valve fragments showed
an increased expression of this receptor when compared
with myocardium tissue.
Aiming to validate gene expression results, in situ
expression of CCL1/I-309, CCL3/MIP1α and CXCL9/
Table 4. In Situ Expression of Chemokines and Chemokine Receptors







2 Mi.v. + + - + - - + +
3 Mi.v. + + - - - + + +



















1 5 Mi.v. + + - - - + + +
1 6 Mi.v. + + - - - + + +



















2 3 Mi.v. + + + - - + + +
“+” occurrence of positive cells; “−” absence of positive cells, Mi.v. mitral valve, Ao.v. aortic valve, R.A. right atrium, L.A. left atrium, Peric. pericardium
806 Faé, Palacios, Nogueira, Oshiro, Demarchi, et al.
Mig, as well as CCR5 and CXCR3, was investigated by
immunoﬂuorescence and confocal microscopy. For this
purpose, myocardium and valvular tissue fragments were
stained with speciﬁc antibodies and subsequently analyzed
by microscopy. Although high gene expression of CCL1/I-
309 was observed in valvular tissue samples as mentioned
above, we observed CCL1-positive cells only in heart
tissue samples of patients 2, 4, and 22 when analyzed by
immunoﬂuorescence (Table 4). In contrast, most of cardiac
tissue samples analyzed presented CXCL9-positive cells
(Table 4). CCL3-positive cells were observed in myocar-
dium sections (patient 22) (Table 4). Additionally, CCR5-
and CXCR3-positive cells were observed in most of the
tissue sections analyzed (Table 4). CCR8 expression was
not determined due to technical problems. Figure 2 depicts
some examples of chemokines and receptors expression in
heart tissue sections.
In Situ Identiﬁcation of Cell Subsets Represented in
the Cardiac Lesions
Cell subsets represented in the cardiac lesions were
stained by immunoﬂuorescence using monoclonal anti-
bodies against T cells (anti-CD4 and anti-CD8) and
macrophages (anti-CD14) (Table 4; Fig. 2). CD4 and
CD8-positive cells were observed in all tissue sections
analyzed; nevertheless, CD14-positive cells were rarely
observed (Table 4). CD4 and CD8 T cells staining are
illustrated in Fig. 2.
Heart-Inﬁltrating T cells from Valvular Tissue
Migrate Toward CXCL9/Mig Gradient In Vitro
To investigate whether CCL1/I-309 and CXCL9/
Mig, chemokines (upregulated in the valvular tissue),
CCL3/MIP1α (upregulated in myocardium), and
CCL17/TARC (equally expressed in valvular and myo-
cardium tissue, data not shown) would affect the
recruitment of T cells to the lesion sites, we performed
a migration assay using pre-established valvular tissue-
inﬁltrating T cell lines in the presence of different
concentrations of chemokines. Valvular tissue-derived
T cell lines were established from tissue fragments from
chronic RHD patients 1, 14, 18, and 19 as previously
described [6].
Phenotypic characterization of the valvular tissue-
inﬁltrating T cell lines prior to chemokine-induced migra-
tion showed that T cell lines from patients 1, 14, and 19
Fig. 2. In situ expression of chemokine and chemokine receptors. Cardiac tissue sections from RHD patients were stained with primary antibodies
against CD4-Alexa Fluor 488, CD8-Alexa Fluor 488, CCL3, CXCL9, CCR5, and CXCR3 followed by incubation with Alexa Fluor 633-conjugated
secondary antibodies. DAPI was used for nuclear staining. Fluorescent images were obtained using an LSM/Meta 510 Zeiss microscope and analysis
was performed using LSM Image Examiner software (Zeiss). The ﬁgure depicts some examples of positive staining from different patients. a, b CD4+
and CD8+ staining (green) in the mitral valve of patient 15; c, d CCR5 and CCL3/MIP1α staining (pink and red, respectively) in the myocardium of
patient 22; e, f CXCL9/Mig and CXCR3 staining (red) in the mitral valve of patient 16.
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were essentially CD4+CD45RO+ T cells, a phenotype
representative of memory T cells. T cell line from patient
18 presented similar percentages of CD4+ and CD8+ T
cells; however, only a few memory CD4+ T cells were
identiﬁed (data summarized on the legend of Table 5).
Notably, CXCL9/Mig gradient induced a signiﬁ-
cant increase in the migration of valvular-tissue inﬁltrat-
ing T cells (Fig. 3a). CCL1/I-309 and CCL17/TARC
gradients induced migration of T cells in a dose-
dependent manner however the results did not reach
statistical signiﬁcance (Fig. 3a). Different concentrations
of CCL3 (MIP1α) seems to not affect valvular-tissue-
derived T cells migration. Of note, CCL3 (MIP1α gene
expression was mostly upregulated in myocardium
tissue samples (Fig. 1).
The percentage of transmigrating cells varied from
2.9 to 7.6 % and were characterized mainly as
CD4+CD45RO+ (Table 5), except cells from patient 18
who presented few CD4+CD45RO+ memory T cells
(3.10 %) before migration (legend Table 5). Figure 3b
shows a representative dot plot of the T cell line derived
from patient 19 pre- and postmigration toward CCL1/I-
309 gradient.
DISCUSSION
Lymphocytic inﬁltration through the valve surface
endothelium is thought to be the initial step for tissue
damage and pathogenesis of RHD. Yet, chemokines and
receptors that mediate cell recruitment to the inﬂamma-
tory sites are unclear. In the present article, we
investigated the expression of several chemokines and
their receptors in clinical tissue samples obtained from
chronic RHD patients. Our results showed a differential
chemokine expression in distinct sites of lesions. CCL3/
MIP1α expression was upregulated in samples from
myocardium; in contrast, CCL1/I-309 and CXCL9/Mig
were upregulated in valvular tissue lesions and can be
considered as important inﬂammatory chemokines that
enhance the severity of valve damage. In addition,
CD4+CD45RO+ valvular tissue-inﬁltrating T cells
migrated toward CXCL9/Mig gradient in vitro.
CCL3/MIP1α is a chemokine produced by several
cell types, such as macrophages, dendritic cells (DCs),
lymphocytes, and endothelial cells. This chemokine
induces recruitment of CCR5+ cells, including
activated and memory T cells, monocytes, macrophages
and immature DCs [16, 17]. Our observation that CCL3/
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patients may indicate that the recruitment of T cells to
the myocardium is the initial step in the development of
the disease, with migration to the valvular tissue
occurring later in disease progression. CCR5 was also
highly expressed in tissue samples analyzed from
rheumatic valvular lesions. This receptor is upregulated
by IFN-γ and TNF-α in tissue-speciﬁc inﬂammation and
Th1 cells [17, 18].
CCL1/I-309 is a chemokine that speciﬁcally binds
to the chemokine receptor CCR8. CCL1/I-309 is mainly
secreted by monocytes, activated lymphocytes and
endothelial cells [19–21], and it is described as a potent
chemoattractant for the same cells [20–23]. Moreover,
CCL1/I-309 has been implicated in the induction of
angiogenesis and the activation of endothelial cells as a
mechanism of valve repair [23]. In our study, CCL1/I-
309 and its receptor CCR8 were upregulated in the
valvular tissue samples; however, CCL1/I-309 gradient
was not effective in inducing signiﬁcant migration of
valvular tissue inﬁltrating T cells. Despite of these
ﬁndings, histological analyses performed in the present
study showed neovascularization as a frequent observa-
Fig. 3. Heart-inﬁltrating T cells migrate towards speciﬁc chemokines gradient. a Absolute numbers of heart inﬁltrating T cells that migrated toward
CCL1/I-309, CCL3/MIP1α, CXCL9/Mig, and CCL17/TARC gradient compared with untreated cells (controls). Data represent mean ± SD of three to
four valvular tissue-derived T cell lines from different RHD patients that transmigrated toward chemokine gradient. Statistical analysis was performed
using nonparametric unpaired t test. P values are depicted in the ﬁgure. b The phenotype of heart tissue-inﬁltrating T cells that migrated toward CCL1/
I-309 gradient (250 nM). The percentage of cells was determined by ﬂow cytometric analysis (FACS) and the results of patient 19 are depicted. Pre-
and post-migration CD4+CD45RO+ and CD8+CD45RO+ subpopulations are shown.
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tion in most of the valvular tissue samples analyzed.
Hence it is tempting to speculate that the expression of
CCL1/I-309 and CCR8 may be a marker of angiogenesis
as mechanism of valve repair. In line with that, increased
expression of factors that induce angiogenesis, such as
VEGF, and decreased expression of anti-angiogenesis
factors, such as condromodulin-I, have already been
described in RHD [24].
CXCL9/Mig is an IFN-γ-inducible chemokine
produced mainly by DCs, B lymphocytes, and macro-
phages [25]. CXCL9/Mig binds to the receptor CXCR3,
which is expressed on multiple cell types but predom-
inantly on memory phenotype cells and primed effector
T cells producing IFN-γ [26]. Our results showed
upregulation of CXCL9/Mig in the valvular tissue and
importantly, CXCL9/Mig gradient induced signiﬁcant
migration of T cells isolated from valvular tissue lesions.
It is important to note that in this study, in situ
expression of CXCR3 was observed in most of the
samples analyzed from valvular tissue. The heart-tissue
inﬁltrating cells resulted from S. pyogenes oligoclonal
primed expansions that are able of recognize valve-
derived proteins as previously described [6, 27] and are
maintained in the valvular tissue upon inﬂammatory
cytokines in line with our previous work in which we
showed that IFNγ-positive mononuclear cells are one of
the major cell types present in cardiac rheumatic lesions
[14]. The in situ production of IFNγ by mononuclear
cells that inﬁltrated both myocardium and valvular tissue
of rheumatic lesions would be the driving factor for the
secretion of CXCL9/Mig by valvular tissue-resident
antigen presenting cells that subsequently recruits
valvular-tissue autoreactive T cells expressing CXCR3.
Altogether, these cells favor a milieu that lead an
inﬂammatory reaction perpetuating the valvular lesions,
consequently leading to the loss of function and heart
failure.
Interestingly, it was demonstrated that combined
blockade of CXCR3 and CCR5 was effective in
preventing acute and chronic allograft rejection in
murine model [28, 29]. In the case of RF, blocking of
CXCR3 could be an effective strategy to control
inﬂammatory activity within the valves. However,
additional studies will be necessary to achieve speciﬁc
blockade of IFN-γ producing T cells recruitment to the
valvular lesions without impairment of effector T cell
responses.
Collectively, this study provides novel evidences
that deﬁned chemokines and receptors that are expressed
in different sites of rheumatic lesions, i.e., myocardium
and valvular tissue. In addition, CXCL9/Mig is the main
chemokine driving T cell recruitment to valvular tissue,
site in which the cardiac deformities are extremely
severe causing permanent damage.
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